Dr. Ferdinandos Skoulidis of UT MD Anderson presents late-breaking results from the Phase 3 KRAScendo 1 trial in the Presidential Symposium at #ESMO26. The findings offer new insig

UT MD Anderson· @UTMDAnderson · X·2026-10-25 23:49· 1 天前评分70

正文 · 原文

Dr. Ferdinandos Skoulidis of UT MD Anderson presents late-breaking results from the Phase 3 KRAScendo 1 trial in the Presidential Symposium at #ESMO26. The findings offer new insights into targeted treatment for patients with previously treated advanced lung cancer with a KRAS G12C mutation.

Learn more: http://spr.ly/6018BH5yCi @FSkoulidis #EndCancer

182 浏览 · 1 赞 · 0 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

来源：UT MD Anderson · x.com